Samuel Isaly’s Orbimed Advisors Sells Some Intercept Pharmaceuticals Stock at $62.50/Share

Orbimed Advisors, Intercept Pharmaceuticals: Samuel Isaly and his hedge fund, Orbimed Advisors, is focused on healthcare stocks. They recently reported selling a piece of their stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Orbimed unloaded 40,088 shares of the company with a selling price of $62.50 apiece, slightly above the current stock price. Following the sale, Orbimed still owns around 1.7 million shares of Intercept.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Disclosure: none